Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.75 USD | +3.50% | +5.63% | -13.10% |
Financials (USD)
Sales 2024 * | 58.64M | Sales 2025 * | 71.15M | Capitalization | 257M |
---|---|---|---|---|---|
Net income 2024 * | 14M | Net income 2025 * | 26M | EV / Sales 2024 * | 4.39 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.62 x |
P/E ratio 2024 * |
17.1
x | P/E ratio 2025 * |
10.1
x | Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 84.7% |
Latest transcript on Fennec Pharmaceuticals Inc.
1 day | +3.50% | ||
1 week | +7.26% | ||
Current month | +6.21% | ||
1 month | -10.47% | ||
3 months | -4.04% | ||
6 months | +25.81% | ||
Current year | -13.10% |
Managers | Title | Age | Since |
---|---|---|---|
Rostislav Raykov
CEO | Chief Executive Officer | 48 | 09-07-06 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 09-07-06 |
Adrian Haigh
COO | Chief Operating Officer | 64 | 14-04-24 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chris Rallis
BRD | Director/Board Member | 70 | 11-08-24 |
Khalid Islam
CHM | Chairman | 67 | 14-04-24 |
Robert Andrade
DFI | Director of Finance/CFO | 49 | 09-07-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 0 M€ | +3.63% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 9.75 | +3.50% | 102,221 |
24-05-09 | 9.42 | +1.62% | 43,646 |
24-05-08 | 9.27 | -0.86% | 38,946 |
24-05-07 | 9.35 | +2.86% | 54,392 |
24-05-06 | 9.09 | -1.52% | 88,712 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.10% | 257M | |
+3.91% | 108B | |
+10.87% | 104B | |
+1.28% | 22.33B | |
-13.14% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.66% | 17.64B | |
+3.75% | 14.05B | |
+36.70% | 12.51B |
- Stock Market
- Equities
- FENC Stock